Clinical Trials Browser

Completed × Interventional × Carcinoid Tumor × Clear all

NCT02826928 2026-01-21

Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors

Phase NA Completed

Carcinoid Tumor

NCT02795858 2025-02-19

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Phase 2 Completed

43 enrolled 11 charts

Carcinoid Tumor

NCT04524442 2025-01-24

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Phase 4 Completed

42 enrolled 11 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Neuroendocrine Tumors

NCT01466036 2024-03-05

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 2 Completed

61 enrolled 9 charts

Carcinoid Tumor, Adenoma, Islet Cell, Neoplasm Metastasis

NCT02318784 2023-12-05

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Phase 2 Completed

62 enrolled 10 charts

Carcinoid Tumor, Carcinoma, Neuroendocrine

NCT01782443 2023-08-14

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Phase 2 Completed

19 enrolled 11 charts

Carcinoid Tumor, Neoplasm Metastasis

NCT00442533 2023-04-03

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Phase 2/3 Completed

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Somatostatinoma, Neuroendocrine Tumors

NCT01253161 2023-03-06

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Phase 2 Completed

29 enrolled 11 charts

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Neuroendocrine Tumors

NCT00774930 2022-10-14

ELECT

Phase 3 Completed

115 enrolled 17 charts

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Phase 4 Completed

34 enrolled 8 charts

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Phase 2 Completed

12 enrolled 21 charts

EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT01263353 2020-12-21

COOPERATE-1

Phase 1 Completed

Carcinoid Tumor

NCT02441062 2020-12-21

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

Phase 2 Completed

122 enrolled 6 charts

CNSEndocrineNET

Carcinoid Tumor, Medulloblastoma, Neuroblastoma, Neuroendocrine Tumors

NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Phase 2 Completed

43 enrolled 12 charts

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT00688623 2019-01-25

RAMSETE/CDE16

Phase 2 Completed

73 enrolled 13 charts

Carcinoid Tumor, Carcinoma, Neuroendocrine Tumors

NCT01435122 2018-10-02

A Study of Axitinib in Advanced Carcinoid Tumors

Phase 2 Completed

30 enrolled 10 charts

Carcinoid Tumor, Neoplasm Metastasis

NCT01024387 2018-03-08

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Phase 2 Completed

60 enrolled 7 charts

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT02132468 2017-12-05

GI-NETorPNET

Phase 2 Completed

18 enrolled 10 charts

Carcinoid Tumor, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00050349 2017-03-01

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Phase 2 Completed

Carcinoid Tumor, Carcinoma, Vipoma, Neoplasm Metastasis, Neoplasms, Gastrinoma, Neuroendocrine Tumors

NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Phase 1 Completed

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00580320 2016-08-18

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Phase 1 Completed

DermatologicEndocrineHead & NeckSarcomaThoracic

Carcinoid Tumor, Melanoma, Parathyroid Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Phase 2 Completed

41 enrolled 9 charts

EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

NCT01396382 2016-03-29

68Ga

Phase 2 Completed

97 enrolled 4 charts

Apudoma, Carcinoid Tumor, Adenoma, Islet Cell, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT00412061 2014-11-21

RADIANT-2

Phase 3 Completed

429 enrolled 13 charts

Carcinoid Tumor, Carcinoma, Malignant Carcinoid Syndrome, Neoplasms

NCT01216267 2013-01-16

Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

Phase NA Completed

Carcinoid Tumor, Carcinoma, Neuroendocrine

NCT00434109 2012-09-14

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Phase 2 Completed

39 enrolled 11 charts

Carcinoid Tumor, Adenoma, Islet Cell, Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

NCT00088595 2012-06-04

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Phase 2 Completed

45 enrolled 10 charts

Carcinoid Tumor, Serotonin Syndrome

NCT00339131 2011-10-12

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

Phase 1 Completed

CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00780663 2011-06-15

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Phase 2 Completed

Carcinoid Tumor, Neuroendocrine Tumors

NCT00328497 2010-03-10

A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors

Phase 2 Completed

Carcinoid Tumor

NCT00388063 2007-12-21

Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Phase 2 Completed

Carcinoid Tumor, Carcinoma, Carcinoma, Neuroendocrine